These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 38003692)

  • 1. Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis.
    Maslennikov R; Poluektova E; Zolnikova O; Sedova A; Kurbatova A; Shulpekova Y; Dzhakhaya N; Kardasheva S; Nadinskaia M; Bueverova E; Nechaev V; Karchevskaya A; Ivashkin V
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut-liver axis signaling in portal hypertension.
    Simbrunner B; Mandorfer M; Trauner M; Reiberger T
    World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of the Gut Microbiome in Liver Cirrhosis Treatment.
    Lee NY; Suk KT
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.
    Chopyk DM; Grakoui A
    Gastroenterology; 2020 Sep; 159(3):849-863. PubMed ID: 32569766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression.
    Chen D; Le TH; Shahidipour H; Read SA; Ahlenstiel G
    Cells; 2019 Oct; 8(11):. PubMed ID: 31717860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are Probiotics Effective in Targeting Alcoholic Liver Diseases?
    Hong M; Han DH; Hong J; Kim DJ; Suk KT
    Probiotics Antimicrob Proteins; 2019 Jun; 11(2):335-347. PubMed ID: 29687200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.
    Giannelli V; Di Gregorio V; Iebba V; Giusto M; Schippa S; Merli M; Thalheimer U
    World J Gastroenterol; 2014 Dec; 20(45):16795-810. PubMed ID: 25492994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update.
    Fukui H
    Gut Liver; 2021 Sep; 15(5):666-676. PubMed ID: 33071239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiota changes and chronic hepatitis C virus infection.
    Preveden T; Scarpellini E; Milić N; Luzza F; Abenavoli L
    Expert Rev Gastroenterol Hepatol; 2017 Sep; 11(9):813-819. PubMed ID: 28621554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential mechanisms linking gut microbiota and portal hypertension.
    Baffy G
    Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.
    Chen YX; Lai LN; Zhang HY; Bi YH; Meng L; Li XJ; Tian XX; Wang LM; Fan YM; Zhao ZF; Han DW; Ji C
    World J Gastroenterol; 2016 Mar; 22(10):2949-59. PubMed ID: 26973391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
    Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
    Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.
    Sorribas M; Jakob MO; Yilmaz B; Li H; Stutz D; Noser Y; de Gottardi A; Moghadamrad S; Hassan M; Albillos A; Francés R; Juanola O; Spadoni I; Rescigno M; Wiest R
    J Hepatol; 2019 Dec; 71(6):1126-1140. PubMed ID: 31295531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension.
    Seo YS; Shah VH
    Clin Mol Hepatol; 2012 Dec; 18(4):337-46. PubMed ID: 23323248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The gut-liver axis in immune remodeling of hepatic cirrhosis.
    Guan H; Zhang X; Kuang M; Yu J
    Front Immunol; 2022; 13():946628. PubMed ID: 37408838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
    Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
    Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of gut microbiota in the pathogenesis and therapeutics of minimal hepatic encephalopathy
    Luo M; Xin RJ; Hu FR; Yao L; Hu SJ; Bai FH
    World J Gastroenterol; 2023 Jan; 29(1):144-156. PubMed ID: 36683714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.